{"schema_version":"secwatch.filing_event.v1","accession":"0001689548-26-000028","form_type":"8-K","ticker":"PRAX","cik":"0001689548","company_name":"Praxis Precision Medicines, Inc.","filed_at":"2026-02-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.896735+00:00","generated_at":"2026-05-16T01:46:52.041115+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Praxis reports Q4 net loss $88.9M; submits two NDAs; cash $926M","bullets":["Net loss $88.9M in Q4 2025 ($303.3M FY), vs $58.7M ($182.8M FY) prior year.","Cash and investments $926.1M at Dec 31, 2025; plus $621.2M Jan 2026 offering funds operations into 2028.","Submitted NDAs to FDA for ulixacaltamide (essential tremor) and relutrigine (SCN2A/SCN8A DEEs).","Topline results expected H1 2026 for vormatrigine Phase 3 (POWER1) and elsunersen EMBRAVE Part A.","Board additions: Jeffrey Kindler, Stuart Arbuckle; promoted Sniecinski to COO, Petrou to President R&D."],"urls":{"canonical":"https://secwatch.observer/filing/0001689548-26-000028","json":"https://secwatch.observer/filing/0001689548-26-000028.json","markdown":"https://secwatch.observer/filing/0001689548-26-000028.md","text":"https://secwatch.observer/filing/0001689548-26-000028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689548/000168954826000028/0001689548-26-000028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689548/000168954826000028/prax-20260219.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:46:52.041115+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}